Wedbush maintains Tango Therapeutics at Outperform, lowers price target to $40 from $45

Jefferies raised its price target for Tango Therapeutics (TNGX) to $65 from $60, citing positive trial data for pancreatic cancer treatments. The stock has surged 187% over the past year. Other analysts also raised price targets, with a consensus Strong Buy rating. The company expects regulatory updates and more data in 2027.

Tango Therapeutics (TNGX) reports Q3 earnings, with focus on its lead cancer drug, vopimetostat. Analysts expect a 35-cent loss per share, no revenue. Shares fell 18% post-data update, but 12/13 analysts rate it buy with $47.09 avg. target. Investors watch for Phase 3 trial timeline and cash burn updates.

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

Tango Therapeutics reported no revenue in 3Q 2026, down from $53.8M a year earlier, with a net loss of $68.39M. R&D and G&A expenses rose, partially offset by higher interest income. Clinical trials for vopimetostat combinations showed promising results. The company plans a global trial in 2027 and will focus on PRMT5 therapies, reducing its workforce by 14%.

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.